Bio-Rad
This article was originally published in The Gray Sheet
Executive Summary
Specialty diagnostics firm's acquisition of Scotland-based Quantase Ltd. will strengthen Bio-Rad's position in newborn screening tests for phenylketonuria, galactosemia and glucose-6-phosphate dehydrogenase deficiency. Financial terms of the deal, announced April 10, are not being disclosed. Bio-Rad estimates the annual newborn screening market at more than $100 mil. worldwide...